Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial

BACKGROUND: Ipilimumab improves survival for patients with metastatic malignant melanoma. Combining a therapeutic cancer vaccine with ipilimumab may increase efficacy by providing enhanced anti-tumor immune responses. UV1 consists of three synthetic long peptides from human telomerase reverse transc...

Descripción completa

Detalles Bibliográficos
Autores principales: Aamdal, Elin, Inderberg, Else Marit, Ellingsen, Espen Basmo, Rasch, Wenche, Brunsvig, Paal Fredrik, Aamdal, Steinar, Heintz, Karen-Marie, Vodák, Daniel, Nakken, Sigve, Hovig, Eivind, Nyakas, Marta, Guren, Tormod Kyrre, Gaudernack, Gustav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147687/
https://www.ncbi.nlm.nih.gov/pubmed/34046035
http://dx.doi.org/10.3389/fimmu.2021.663865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147687/
https://www.ncbi.nlm.nih.gov/pubmed/34046035
http://dx.doi.org/10.3389/fimmu.2021.663865

Ejemplares similares